STEMI resident survival guide: Difference between revisions

Jump to navigation Jump to search
Line 81: Line 81:


{{Family tree/start}}
{{Family tree/start}}
{{familytree  | | | | | | | A01 | | | | | | A01= '''Initial Treatment'''<br> <div style="float: left; text-align: left; width: 30em; padding:1em;"> ❑ Administer 300 mg [[aspirin]]<ref name="pmid18574276">{{cite journal| author=Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ et al.| title=Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | journal=Chest | year= 2008 | volume= 133 | issue= 6 Suppl | pages= 670S-707S | pmid=18574276 | doi=10.1378/chest.08-0691 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18574276  }} </ref> <br>
{{familytree  | | | | | A01 | | | | | A01= '''Initial Treatment'''<br> <div style="float: left; text-align: left; width: 30em; padding:1em;"> ❑ Administer 300 mg [[aspirin]]<ref name="pmid18574276">{{cite journal| author=Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ et al.| title=Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | journal=Chest | year= 2008 | volume= 133 | issue= 6 Suppl | pages= 670S-707S | pmid=18574276 | doi=10.1378/chest.08-0691 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18574276  }} </ref> <br>
❑ Administer [[oxygen]] in patients with saturation <90%<ref name="pmid23554440">{{cite journal| author=Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S et al.| title=Oxygen therapy in acute coronary syndrome: are the benefits worth the risk? | journal=Eur Heart J | year= 2013 | volume= 34 | issue= 22 | pages= 1630-5 | pmid=23554440 | doi=10.1093/eurheartj/eht110 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23554440  }} </ref><br>
❑ Administer [[oxygen]] in patients with saturation <90%<ref name="pmid23554440">{{cite journal| author=Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S et al.| title=Oxygen therapy in acute coronary syndrome: are the benefits worth the risk? | journal=Eur Heart J | year= 2013 | volume= 34 | issue= 22 | pages= 1630-5 | pmid=23554440 | doi=10.1093/eurheartj/eht110 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23554440  }} </ref><br>
❑ Administer sublingual [[nitroglycerine]], (0.4-0.8 mg)<ref name="pmid10704160">{{cite journal| author=Doucet S, Malekianpour M, Théroux P, Bilodeau L, Côté G, de Guise P et al.| title=Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. | journal=Circulation | year= 2000 | volume= 101 | issue= 9 | pages= 955-61 | pmid=10704160 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10704160  }} </ref> <br>
❑ Administer sublingual [[nitroglycerine]], (0.4-0.8 mg)<ref name="pmid10704160">{{cite journal| author=Doucet S, Malekianpour M, Théroux P, Bilodeau L, Côté G, de Guise P et al.| title=Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. | journal=Circulation | year= 2000 | volume= 101 | issue= 9 | pages= 955-61 | pmid=10704160 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10704160  }} </ref> <br>
Line 90: Line 90:
:❑ [[Fondaparinux]], or<br>
:❑ [[Fondaparinux]], or<br>
:❑ [[UFH]] in case of [[renal failure]]<ref name="pmid16537663">{{cite journal| author=Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J et al.| title=Comparison of fondaparinux and enoxaparin in acute coronary syndromes. | journal=N Engl J Med | year= 2006 | volume= 354 | issue= 14 | pages= 1464-76 | pmid=16537663 | doi=10.1056/NEJMoa055443 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16537663  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16944851 Review in: ACP J Club. 2006 Sep-Oct;145(2):30-1] </ref>  </div>}}
:❑ [[UFH]] in case of [[renal failure]]<ref name="pmid16537663">{{cite journal| author=Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J et al.| title=Comparison of fondaparinux and enoxaparin in acute coronary syndromes. | journal=N Engl J Med | year= 2006 | volume= 354 | issue= 14 | pages= 1464-76 | pmid=16537663 | doi=10.1056/NEJMoa055443 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16537663  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16944851 Review in: ACP J Club. 2006 Sep-Oct;145(2):30-1] </ref>  </div>}}
{{familytree | | | | | | | |!| | | | | | | }}
{{familytree | | | | | |!| | | | | | }}
{{familytree | | | | | | | B01 | | | | | | B01=<div style="float: left; text-align: center; width: 30em; padding:1em;">'''Is PCI available?''' </div>}}
{{familytree | | | | | B01 | | | | | | B01=<div style="float: left; text-align: center; width: 30em; padding:1em;">'''Is PCI available?''' </div>}}
{{familytree | | | |,|-|-|-|^|-|-|-|.| | | }}
{{familytree | | |,|-|-|^|-|-|-|.| | }}
{{familytree | | | C01 | | | | | | C02 | | C01=<div style="float: left; text-align: center; width: 15em; padding:1em;">'''Yes''' </div>| C02= <div style="float: left; text-align: center; width: 15em; padding:1em;">'''No''' </div> }}
{{familytree | | C01 | | | | | C02 | | C01=<div style="float: left; text-align: center; width: 15em; padding:1em;">'''Yes''' </div>| C02= <div style="float: left; text-align: center; width: 15em; padding:1em;">'''No''' </div> }}
{{familytree | | | |!| | | | | | | |!| | | }}
{{familytree | | |!| | | | | | |!| | | }}
{{familytree | | | D01 | | | | | | D02 | | | |D01=<div style="float: left; text-align: left; width: 20em; padding:1em;">❑ Send to cath lab for primary PCI</div>| D02=<div style="float: left; text-align: left; width: 20em; padding:1em;"> Evaluate for <br> ❑ The time from onset of symptoms <br> ❑ The risk of complications related to STEMI <br> ❑ The risk of bleeding with fibrinolysis <br> ❑ The presence of shock or severe HF <br> ❑ The time required for transfer to a PCI-capable hospital  </div>}}
{{familytree | | D01 | | | | | D02 | | | |D01=<div style="float: left; text-align: left; width: 20em; padding:1em;">❑ Send to cath lab for primary PCI</div>| D02=<div style="float: left; text-align: left; width: 20em; padding:1em;"> Evaluate for <br> ❑ The time from onset of symptoms <br> ❑ The risk of complications related to STEMI <br> ❑ The risk of bleeding with fibrinolysis <br> ❑ The presence of shock or severe HF <br> ❑ The time required for transfer to a PCI-capable hospital  </div>}}
{{familytree | | | |!| | | | | |,|-|^|-|.| | |}}
{{familytree | | |!| | | | |,|-|^|-|.| }}
{{familytree | | | E01 | | | | E02 | | E03 | | E01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Administer one of the following antiplatelet agents:'''</div> | E02=<div style="float: left; text-align: left; width: 15em; padding:1em;">❑ Transfer for primary PCI <br> ❑ FMC to device time as soon as possible and ≤ 120 min. </div>| E03=<div style="float: left; text-align: left; width: 15em; padding:1em;"> ❑ Administer fibrinolytic agent within 30 min of arrival </div>}}
{{familytree | | E01 | | | E02 | | E03 | E01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Administer one of the following antiplatelet agents:'''</div> | E02=<div style="float: left; text-align: left; width: 15em; padding:1em;">❑ Transfer for primary PCI <br> ❑ FMC to device time as soon as possible and ≤ 120 min. </div>| E03=<div style="float: left; text-align: left; width: 15em; padding:1em;"> ❑ Administer fibrinolytic agent within 30 min of arrival </div>}}
{{familytree | | | |!| | | | | | | | | }}
{{familytree | | |!| | | | | | | | | }}
{{familytree | | | F01 | | | | F01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Before PCI'''<br>
{{familytree | | F01 | | | | F01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Before PCI'''<br>
❑ [[P2Y12]] receptor inhibitors <br>
❑ [[P2Y12]] receptor inhibitors <br>
:❑ [[Clopidogrel]] (600 mg), or<br>
:❑ [[Clopidogrel]] (600 mg), or<br>
Line 110: Line 110:
::❑ Loading dose 25 mcg/kg<br>
::❑ Loading dose 25 mcg/kg<br>
::❑ Maintenance dose 0.15 mcg/kg/min</div>}}
::❑ Maintenance dose 0.15 mcg/kg/min</div>}}
{{familytree | | | |!| | | | | | | | | }}
{{familytree | | |!| | | | | | | | | }}
{{familytree | | | G01 | | | | G01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''At the time of PCI'''<br>
{{familytree | | G01 | | | | G01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''At the time of PCI'''<br>
❑ [[P2Y12]] receptor inhibitors <br>
❑ [[P2Y12]] receptor inhibitors <br>
:❑ [[Clopidogrel]] (600 mg), or<br>
:❑ [[Clopidogrel]] (600 mg), or<br>

Revision as of 21:02, 3 March 2014


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Definition

ST elevation myocardial infarction (STEMI) is a syndrome defined by symptoms of myocardial ischemia (sudden chest pain and pressure, shortness of breath) associated with persistent ECG ST elevation and subsequent release of cardiac enzymes.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. STEMI is a life-threatening condition and must be treated as such irrespective of the causes.

Common Causes

Management

Diagnostic Approach

Shown below is an algorithm summarizing the diagnostic approach to STEMI based on the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction[1]



 
 
 
 
 
Characterize the symptoms:

Chest pain

❑ Sudden onset
❑ Described as a sensation of tightness, pressure, or squeezing
❑ Radiation to the jaw or left arm
❑ No relief with medications or rest
❑ Worse with time
❑ Shortness of breath (Dyspnea)

Diaphoresis
Light-headedness

Nausea and/or vomiting
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obtain a detailed history:

❑ Age
❑ Previous MI
❑ Previous PCI or CABG
❑ Cardiac risk factors:

Hypertension
Diabetes
Hypercholesterolemia
Smoking
Obesity
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:

❑ Measure the blood pressure
❑ Measure the heart rate
❑ Auscultate the heart searching for murmurs
❑ Search for signs of CHF

❑ Decreased air entry in the lungs
❑ Edema in the extremities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rule out life threatening alternative diagnoses:

Aortic dissection
Pulmonary embolism
Cardiac tamponade
Tension pneumothorax

Esophageal rupture
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order labs and tests:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order EKG
❑ New ST elevation at the J point in at least 2 contiguous leads of 2 mm (0.2 mV) in men or 1.5 mm (0.15 mV) in women in leads V2–V3 and/or of 1 mm (0.1 mV) in other contiguous chest leads or the limb leads
❑ For EKG examples click here
 
Order Cardiac Enzymes
Troponin I
CK-MB
 
Other labs:

Creatinine
Glucose

Hemoglobin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Symptoms + increase in Troponin
+ EKG ST elevation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Start treatment for STEMI
 
 
 
 
 

Therapeutic Apporach

Shown below is an algorithm depicting the therapeutic approach to STEMI based on the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction.[1]

 
 
 
 
Initial Treatment
❑ Administer 300 mg aspirin[2]

❑ Administer oxygen in patients with saturation <90%[3]
❑ Administer sublingual nitroglycerine, (0.4-0.8 mg)[4]
❑ Administer morphine IV (initial dose 2-4 mg with increments of 2-8 mg every 5 to 15 minutes)
❑ Administer beta-blockers (unless contraindicated)[5] [6]
❑ Administer statins (atorvastatin, 80 mg)[7]
❑ Administer antithrombotic treatment

Fondaparinux, or
UFH in case of renal failure[8]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Is PCI available?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Send to cath lab for primary PCI
 
 
 
 
Evaluate for
❑ The time from onset of symptoms
❑ The risk of complications related to STEMI
❑ The risk of bleeding with fibrinolysis
❑ The presence of shock or severe HF
❑ The time required for transfer to a PCI-capable hospital
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Administer one of the following antiplatelet agents:
 
 
❑ Transfer for primary PCI
❑ FMC to device time as soon as possible and ≤ 120 min.
 
❑ Administer fibrinolytic agent within 30 min of arrival
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before PCI

P2Y12 receptor inhibitors

Clopidogrel (600 mg), or
Ticagrelor (180 mg), or

❑ IV GP IIb/IIIa inhibitors

Eptifibatide
❑ Loading dose 180 mcg/kg IV bolus followed by another bolus after 10 minutes
❑ Maintenance dose 2 mcg/kg/min, or
Tirofiban
❑ Loading dose 25 mcg/kg
❑ Maintenance dose 0.15 mcg/kg/min
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At the time of PCI

P2Y12 receptor inhibitors

Clopidogrel (600 mg), or
Ticagrelor (180 mg), or
❑ Prasugrel (60 mg)

❑ IV GP IIb/IIIa inhibitors

Eptifibatide
❑ Loading dose 180 mcg/kg IV bolus followed by another bolus after 10 minutes
❑ Maintenance dose 2 mcg/kg/min, or
Tirofiban
❑ Loading dose 25 mcg/kg
❑ Maintenance dose 0.15 mcg/kg/min
 
 
 

References

  1. 1.0 1.1 O'Gara, Patrick T.; Kushner, Frederick G.; Ascheim, Deborah D.; Casey, Donald E.; Chung, Mina K.; de Lemos, James A.; Ettinger, Steven M.; Fang, James C.; Fesmire, Francis M.; Franklin, Barry A.; Granger, Christopher B.; Krumholz, Harlan M.; Linderbaum, Jane A.; Morrow, David A.; Newby, L. Kristin; Ornato, Joseph P.; Ou, Narith; Radford, Martha J.; Tamis-Holland, Jacqueline E.; Tommaso, Carl L.; Tracy, Cynthia M.; Woo, Y. Joseph; Zhao, David X. (2013). "2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction". Journal of the American College of Cardiology. 61 (4): e78–e140. doi:10.1016/j.jacc.2012.11.019. ISSN 0735-1097.
  2. Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ; et al. (2008). "Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest. 133 (6 Suppl): 670S–707S. doi:10.1378/chest.08-0691. PMID 18574276.
  3. Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S; et al. (2013). "Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?". Eur Heart J. 34 (22): 1630–5. doi:10.1093/eurheartj/eht110. PMID 23554440.
  4. Doucet S, Malekianpour M, Théroux P, Bilodeau L, Côté G, de Guise P; et al. (2000). "Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty". Circulation. 101 (9): 955–61. PMID 10704160.
  5. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL; et al. (2007). "Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention". Circulation. 115 (21): 2761–88. doi:10.1161/CIRCULATIONAHA.107.183885. PMID 17502569.
  6. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H; et al. (2004). "Expert consensus document on beta-adrenergic receptor blockers". Eur Heart J. 25 (15): 1341–62. doi:10.1016/j.ehj.2004.06.002. PMID 15288162.
  7. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R; et al. (2004). "Intensive versus moderate lipid lowering with statins after acute coronary syndromes". N Engl J Med. 350 (15): 1495–504. doi:10.1056/NEJMoa040583. PMID 15007110. Review in: ACP J Club. 2004 Sep-Oct;141(2):33
  8. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J; et al. (2006). "Comparison of fondaparinux and enoxaparin in acute coronary syndromes". N Engl J Med. 354 (14): 1464–76. doi:10.1056/NEJMoa055443. PMID 16537663. Review in: ACP J Club. 2006 Sep-Oct;145(2):30-1


Template:WikiDoc Sources